![]() ![]() The drug consists of three main components: Antibody (targeting) - Linker (linking the antibody to the payload) - Payload (killing tumor cells).įig. According to a publication in Nature Reviews Drug Discovery in 2021, the global ADC drug market will reach $16.4 billion by 2026ĪDCs are designed to reduce systemic exposure and improve safety by bringing cytotoxic drugs around cancer cells based on antibody targeting. Antibody Drug Conjugates (ADC)Īntibody drug conjugates (ADCs) are currently the most successful type of drug conjugates, with the largest number of drugs listed and promising clinical benefits and commercial value. In this article, we briefly introduce the technical features and representative project development progress of several kinds of drug conjugates. In addition, new technical forms such as antibody degraducer conjugates (ADeC) are still emerging. ![]() Nowadays, a variety of new conjugation technology concepts have emerged, including peptide drug conjugates (PDC), small molecule-drug conjugates (SMDC), immune-stimulating antibody conjugate (ISAC), antibody-oligonucleotide conjugates (AOC), radionuclide drug conjugates (RDC), antibody fragment-drug conjugates (FDC), aptamer drug conjugates (ApDC), antibody cell drug conjugates (ACC), virus-like drug conjugates (VDC), etc. And the technological advances have led to the intertwined collision of old and new ideas of drug conjugates, which have even challenged the current concepts and technologies. Drug conjugates, especially antibody drug conjugates (ADCs), have attracted widespread attention for their clinical outcomes and potential commercial value. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |